Palisade Bio Inc PALI

$1.23 -0.10 (-7.52%)

Valuation

Market cap
231,780,000
Revenue TTM
$0
Net income TTM
$-16,780,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,703,100
Avg volume
2,660,332
Day's range
$1.21 – $1.35
Shares out
174,271,000
Stochastic %K
17%
Beta
1.61
Analysts
Strong Sell
Price target
$10.00

Price

Company profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease...

Show more

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Industry
Biotechnology
Sector
Healthcare
Phone
858 704 4900
Website
https://www.palisadebio.com
Address
4600 South Syracuse Street, Suite 900, Denver, United States

Latest news

No headlines yet.

Stocktwits

calibran_de Oct 26, 3:13 PM
$PALI What’s happening with the stock price right now? Bad news?
0 replies
ClearingMoney Oct 26, 1:27 AM
$PALI News ?
0 replies
NeonNestEgg Oct 25, 2:50 AM
$PALI really want to believe there’s something good waiting here
0 replies
ajbski Oct 23, 2:46 PM
$PALI The lack of market reaction to what should be a highly significant catalyst never ceases to baffle. The recent PALI-2108 Posters at UEG Week 2026 should have sent the pps soaring, but instead the pps has dropped. Crazy. Phase 2 ACENTRA-UC results will confirm the disruptive potential of PALI-2108 in treating IBD. This trial is now recruiting patients, with over 115 locations participating. https://clinicaltrials.gov/study/NCT07845487?intr=PALI-2108&viewType=Card&rank=3 See summary of UEG 2026 PALI-2108 Posters:
0 replies
ajbski Oct 21, 3:54 PM
$PALI Oppenheimer reiterates Palisade Bio outperform rating with an $8.00 PT on Crohn’s data. Analyst consensus remains bullish with a Strong Buy rating and price targets ranging from $5 to $25. Published Oct 21, 2026, 04:53 AM https://www.investing.com/news/analyst-ratings/oppenheimer-reiterates-palisade-bio-stock-rating-on-crohns-data-93CH-4962017
0 replies
ajbski Oct 21, 1:18 PM
$PALI PALI-2108: Disruptive Potential In Gastrointestinal Medicine: https://share.google/aimode/LLi6ss131bp3nyYtt
0 replies
prismmarketview Oct 20, 6:33 PM
$PALI: PALI-2108 data at UEG Week 2026 → Crohn’s (n=5, 14 days): endoscopic activity -47.5%, fecal calprotectin -58.8%; 2 endoscopic response, 2 endoscopic remission → UC (n=5, 7 days): clinical response in all five → Tissue levels ~7.3x peak blood levels (Crohn’s) → Enrolling Phase 2b UC; initiating Phase 2a Crohn’s Caveats: tiny studies, no placebo; 4 of 5 Crohn’s patients on biologics. Not approved. $PALI #Biotech https://prismmarketview.com/palisade-bio-reports-early-crohns-disease-improvements-as-pali-2108-advances-in-phase-2/
0 replies
YouVSYou Oct 20, 1:15 PM
$PALI had news maybe a bounce at 1.32 $YMAT 2.36 keybreak. $HTZ no more fun Unless 2.10/2.29 above
0 replies